论文部分内容阅读
目的探讨单倍型骨髓移植治疗血液系统恶性组织细胞病(恶组)的造血重建、移植相关并发症的发生。方法对1例20岁男性恶组患者进行单倍型骨髓移植,供者为患者之父,HLA2个位点不合。预处理方案:采用白消安加环磷酰胺(Bu/Cy)方案,加用抗淋巴细胞球蛋白(ALG)。移植物抗宿主病(GVHD)的预防采用环孢菌素A(CsA)联合短程甲氨蝶呤(MTX)和骁悉(MMF)的方案,移植有核细胞数为4.3×108/kg。结果移植后+20天中性粒细胞数>0.5×109/L,移植后+25天血小板计数>20×109/L,移植后+46天全血细胞恢复正常。移植后2个月血型由O型转为A型。结论单倍型骨髓移植治疗恶性组织细胞病是可行的。
Objective To investigate the hematopoietic reconstitution and transplantation-related complications of haploidentical bone marrow transplantation in the treatment of malignant histiocytosis (malignant) hematological malignancies. Methods A haplotype bone marrow transplantation was performed on a 20-year-old man with malignant group. The donor was the father of the patient and the HLA2 loci were not matched. Preconditioning regimen: Adriamycin plus cyclophosphamide (Bu / Cy) regimen plus anti-lymphocyte globulin (ALG). Prevention of graft-versus-host disease (GVHD). Cyclosporine A (CsA) combined with short-course methotrexate (MTX) and MMF was used and the number of transplanted nucleated cells was 4.3 × 108 / kg. Results The number of neutrophils was> 0.5 × 109 / L at +20 days after transplantation, and the platelet count was> 20 × 109 / L at +25 days after transplantation. The whole blood cells returned to normal on +46 days after transplantation. 2 months after transplantation blood type from O to A type. Conclusion haploidentical bone marrow transplantation is feasible for malignant histiocytosis.